Cantor Fitzgerald Weighs in on Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Prothena in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biotechnology company will post earnings per share of ($3.97) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business’s quarterly revenue was down 98.9% on a year-over-year basis. During the same quarter last year, the company posted $0.38 earnings per share.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Chardan Capital assumed coverage on shares of Prothena in a report on Friday, December 20th. They issued a “buy” rating and a $40.00 price objective on the stock. Bank of America reduced their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price target (down from $84.00) on shares of Prothena in a report on Friday, December 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Prothena Stock Up 2.5 %

Shares of PRTA opened at $14.11 on Wednesday. The stock has a 50-day moving average of $14.35 and a two-hundred day moving average of $18.04. Prothena has a one year low of $11.70 and a one year high of $34.75.

Institutional Trading of Prothena

A number of hedge funds have recently added to or reduced their stakes in PRTA. Duncan Williams Asset Management LLC raised its position in shares of Prothena by 41.9% in the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 20,450 shares during the period. SG Americas Securities LLC raised its holdings in Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company’s stock worth $521,000 after purchasing an additional 23,525 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in Prothena in the 4th quarter worth about $724,000. Barclays PLC grew its holdings in Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 49,916 shares during the period. Finally, Orion Portfolio Solutions LLC increased its position in shares of Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock valued at $293,000 after buying an additional 739 shares in the last quarter. 97.08% of the stock is owned by hedge funds and other institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.